JP2023511774A5 - - Google Patents
Info
- Publication number
- JP2023511774A5 JP2023511774A5 JP2022546621A JP2022546621A JP2023511774A5 JP 2023511774 A5 JP2023511774 A5 JP 2023511774A5 JP 2022546621 A JP2022546621 A JP 2022546621A JP 2022546621 A JP2022546621 A JP 2022546621A JP 2023511774 A5 JP2023511774 A5 JP 2023511774A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- represented
- antibody
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968252P | 2020-01-31 | 2020-01-31 | |
| US62/968,252 | 2020-01-31 | ||
| US202063055405P | 2020-07-23 | 2020-07-23 | |
| US63/055,405 | 2020-07-23 | ||
| PCT/US2021/012666 WO2021154476A1 (en) | 2020-01-31 | 2021-01-08 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511774A JP2023511774A (ja) | 2023-03-22 |
| JP2023511774A5 true JP2023511774A5 (https=) | 2024-01-18 |
| JP7807379B2 JP7807379B2 (ja) | 2026-01-27 |
Family
ID=77079923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546621A Active JP7807379B2 (ja) | 2020-01-31 | 2021-01-08 | 抗トランスフェリン受容体（ｔｆｒ）抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230113823A1 (https=) |
| EP (1) | EP4096695A4 (https=) |
| JP (1) | JP7807379B2 (https=) |
| KR (1) | KR20220134584A (https=) |
| CN (1) | CN115427059A (https=) |
| AU (1) | AU2021213042A1 (https=) |
| BR (1) | BR112022014771A2 (https=) |
| CA (1) | CA3163290A1 (https=) |
| IL (1) | IL295022A (https=) |
| MX (1) | MX2022009418A (https=) |
| WO (1) | WO2021154476A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20250058123A (ko) * | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| WO2024168801A1 (zh) * | 2023-02-17 | 2024-08-22 | 南京融捷康生物科技有限公司 | 抗TfR1的单域抗体及其用途 |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025265092A1 (en) * | 2024-06-21 | 2025-12-26 | Dyne Therapeutics, Inc. | Complexes and uses thereof for treating pompe disease |
| CN120209138B (zh) * | 2025-05-29 | 2025-10-03 | 杭州广科安德生物科技有限公司 | Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| KR20160047567A (ko) * | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| RU2737637C2 (ru) * | 2015-07-22 | 2020-12-01 | Инатерис | Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств |
| CA2997809A1 (en) * | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| US11859002B2 (en) * | 2016-05-13 | 2024-01-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| KR102497564B1 (ko) | 2016-12-26 | 2023-02-07 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체 |
| AU2018224094B2 (en) * | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| AU2018378812B2 (en) * | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| IL276327B2 (en) | 2018-02-05 | 2024-05-01 | Japan Chem Res | Method for delivering drug to muscle |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
-
2021
- 2021-01-08 CN CN202180025161.4A patent/CN115427059A/zh active Pending
- 2021-01-08 US US17/796,418 patent/US20230113823A1/en active Pending
- 2021-01-08 BR BR112022014771A patent/BR112022014771A2/pt unknown
- 2021-01-08 IL IL295022A patent/IL295022A/en unknown
- 2021-01-08 AU AU2021213042A patent/AU2021213042A1/en active Pending
- 2021-01-08 MX MX2022009418A patent/MX2022009418A/es unknown
- 2021-01-08 EP EP21748405.4A patent/EP4096695A4/en active Pending
- 2021-01-08 JP JP2022546621A patent/JP7807379B2/ja active Active
- 2021-01-08 KR KR1020227029398A patent/KR20220134584A/ko active Pending
- 2021-01-08 CA CA3163290A patent/CA3163290A1/en active Pending
- 2021-01-08 WO PCT/US2021/012666 patent/WO2021154476A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511774A5 (https=) | ||
| CN112646031B (zh) | 抗4-1bb纳米抗体及其用途 | |
| US9758586B2 (en) | Chimeric rabbit/human ROR1 antibodies | |
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| WO2020168555A1 (zh) | Cd3抗原结合片段及其应用 | |
| AU2010238723A1 (en) | Anti-human ROR1 antibodies | |
| TW201026325A (en) | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment | |
| KR20140034877A (ko) | 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도 | |
| CN110856446A (zh) | 抗pd-l1抗体及其用途 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| KR20230125042A (ko) | 항-tslp 나노항체 및 이의 응용 | |
| JP7755062B2 (ja) | 新規抗ｌ１ｃａｍ抗体 | |
| WO2021155635A1 (zh) | 抗cd3和cd123双特异性抗体及其用途 | |
| TW202506189A (zh) | 配體－細胞毒性藥物綴合物及其醫藥用途 | |
| CN120712286A (zh) | 抗体、抗原结合片段和使用方法 | |
| US20240075158A1 (en) | Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof | |
| TW202535883A (zh) | 配體–細胞毒性藥物偶聯物及其藥物用途 | |
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| JP2025506248A5 (https=) | ||
| IL324637A (en) | Antibody specifically binding to cll1, and preparation method therefor and use thereof | |
| CN120424212A (zh) | 抗FGFR2b抗体及抗体药物偶联物 | |
| TW202432185A (zh) | 配體－細胞毒性藥物綴合物及其藥物用途 | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| TWI843182B (zh) | 一種抗b7-h4抗體及其製備方法和應用 | |
| TW202434637A (zh) | 抗體、抗原結合片段及其醫藥用途 |